Articles

Potential to treat Pompe disease

Findings validate gene therapy approach
Written byIlene Schneider
| 3 min read

CRANBURY, N.J.—Pompe disease, a fatal neuromuscular and motorneuron disorder, affects 5,000 to 10,000 people worldwide. Caused by deficiency of the enzyme acid alpha-glucosidase (GAA), the inherited lysosomal storage disorder can lead to the accumulation of glycogen in cells.

The debilitating disease is characterized by severe muscle weakness that worsens over time. Pompe disease ranges from a rapidly fatal infantile form significantly impacting heart function to a more slowly progressive, late-onset form primarily affecting skeletal muscle. Respiratory and cardiac failure are the leading causes of morbidity and mortality.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.